egSEQ Comprehensive Oncology Panel is a hybridisation-based targeted sequencing panel covering >600 genes, as well as important MSI and fusion sites related to solid tumours and targeted therapies, allowing accurate, comprehensive and cost-effective analysis of all types of mutations, including SNVs, InDels, CNVs, and rearrangements. egSEQ Comprehensive Oncology Panel provides a comprehensive approach to analysing actionable biomarkers relevant to oncological diagnosis, prognosis, and therapy with tissue, FFPE and cfDNA samples.
 
Features
Including important genes and fusion intron regions.
TMB and MSI for immunotherapy evaluation.
Market-leading capture efficiency of up to 75% and exceptional uniformity with 20X > 99%.
Available with UMI adapter for more precise analysis.
 
Applications
Targeted therapy and concomitant diagnosis.
Mutation analysis of tumour-related genes.
Suitable for patients with existing solid tumours and those with a family history.